These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

36 related articles for article (PubMed ID: 21278576)

  • 21. Treatment adherence and persistence with duloxetine, venlafaxine XR, and escitalopram among patients with major depressive disorder and chronic pain-related diseases.
    Wang J; Liu X; Mullins CD
    Curr Med Res Opin; 2011 Jul; 27(7):1303-13. PubMed ID: 21561393
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early discontinuation and suboptimal dosing of duloxetine treatment in patients with major depressive disorder: analysis from a US third-party payer perspective.
    Cui Z; Faries DE; Gelwicks S; Novick D; Liu X
    J Med Econ; 2012; 15(1):134-44. PubMed ID: 22014076
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trajectory analysis of healthcare costs for patients with major depressive disorder treated with high doses of duloxetine.
    Cui Z; Faries DE; Zhao Y; Novick D; Liu X
    J Med Econ; 2011; 14(5):662-72. PubMed ID: 21892857
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Initial duloxetine prescription dose and treatment adherence and persistence in patients with major depressive disorder.
    Liu X; Gelwicks S; Faries DE; Able SL
    Int Clin Psychopharmacol; 2010 Nov; 25(6):315-22. PubMed ID: 20706125
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Medication adherence and healthcare costs among fibromyalgia patients treated with duloxetine.
    Zhao Y; Chen SY; Wu N; Fraser KA; Boulanger L
    Pain Pract; 2011; 11(4):381-91. PubMed ID: 21199311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adherence and persistence with duloxetine and hospital utilization in patients with major depressive disorder.
    Liu X; Tepper PG; Able SL
    Int Clin Psychopharmacol; 2011 May; 26(3):173-80. PubMed ID: 21278576
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials.
    Hudson JI; Wohlreich MM; Kajdasz DK; Mallinckrodt CH; Watkin JG; Martynov OV
    Hum Psychopharmacol; 2005 Jul; 20(5):327-41. PubMed ID: 15912562
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression.
    Shelton RC; Prakash A; Mallinckrodt CH; Wohlreich MM; Raskin J; Robinson MJ; Detke MJ
    Int J Clin Pract; 2007 Aug; 61(8):1337-48. PubMed ID: 17627710
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression.
    Cowen PJ; Ogilvie AD; Gama J
    Curr Med Res Opin; 2005 Mar; 21(3):345-56. PubMed ID: 15811202
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Duloxetine: pharmacoeconomic implications of an antidepressant that alleviates painful physical symptoms.
    McIntyre RS; Konarski JZ
    Expert Opin Pharmacother; 2005 May; 6(5):707-13. PubMed ID: 15934897
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical and economic impact of non-adherence to antidepressants in major depressive disorder: A systematic review.
    Ho SC; Chong HY; Chaiyakunapruk N; Tangiisuran B; Jacob SA
    J Affect Disord; 2016 Mar; 193():1-10. PubMed ID: 26748881
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 33.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 2.